Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications

NCT02649790 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT02649790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02649790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2016
Completion date
December 23, 2024
Enrollment
277 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), higher-risk myelodysplastic syndrome (hr-mds), metastatic castration-resistant prostate cancer (mcrpc), metastatic colorectal cancer (mcrc), newly diagnosed intermediate/high-risk mds, relapsed/refractory multiple myeloma (rrmm)